Stemline soars on coverage initiations

Stemline Therapeutics (STML +13.2%) posts double-digit gains in morning trading.

Roth Capital starts the shares at Buy with a $50 price target, representing a 110% upside from Monday's close.

LifeScience Advisors initiates coverage as well.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs